AURINIA PHARMACEUTICALS INC.

ISIN: CA05156V1022 WKN: 05156V102 Asset Class: Stock



Company Profile

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023	2	022	20	21
Financial figures	Assets Liabilities	and equity Asset	s Liabilities and equity	Assets	Liabilities and equity
Current assets	-		-	-	
Common stock capital		-	-		
Fixed assets	-		-	-	
Equity capital of a company		-			
Cash and cash equivalents	-		-	-	
Accrued liabilities		-	-		
Other assets	-		-	-	
Current liabilities		-	-		
Prepayments and accrued income	-		-	-	
Non-current liabilities		-			
Different income		-	-		
Other liabilities		-	-		
Total assets	-	-		-	

Balance notes

	2023	2022	2021
Accounting standard	-	-	-
Employees	-	-	-
Equity ratio	68.96%	86.11%	88.17%
Debt-equity ratio	45.01%	16.14%	13.42%

Others

	2023	2022	2021
Tax Expense Rate	-0.71%	-1.72%	-0.42%

AURINIA PHARMACEUTICALS INC.

ISIN: CA05156V1022 WKN: 05156V102 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	-	-	-
Net income		-	-
EBIT	-85,694,409	-104,179,862	-168,420,528
Operating income before taxes		-	-
Cash Flow	-	-	-
Net interest income	-	-	-
Research and development expenses	-	-	-
Income taxes	-	-	-
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	546,781	417,548	142,075

Board of Directors

Members of Management Board

Daniel Billen	Chairman of Supervisory Board	
Brinda Balakrishnan	Member of Supervisory Board	
David Jaynee	Member of Supervisory Board	
Karen Smith	Member of Supervisory Board	
Robert Foster	Member of Supervisory Board	
Jeffrey Bailey	Member of Supervisory Board	
Jill Leversage	Member of Supervisory Board	
R. MacKay-Dunn	Member of Supervisory Board	